Jean Elwing, MD
Pulmonary Disease · Cincinnati, OHNPI 1164503355
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $245,689 of the $320,171 with a category attached, or 76.7%. 15 manufacturers reported payments, led by United Therapeutics Corporation at 46.6% of the total. 2025 is the largest year on record at $90,376, more than ten times the $7,135 reported in 2019. Among pulmonary disease clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 386 payments — averaging $829.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$149K
- Merck$62K
- Actelion Pharmaceuticals US, Inc.$58K
- Bayer$26K
- Actelion Pharmaceuticals, Ltd$18K
- Insmed, Inc.$5K
- plus $2K from 9 others
Across 184 payments — averaging $11,210 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.4M
- United Therapeutics Corporation$416K
- Janssen Research & Development, LLC$136K
- Sumitomo Pharma America, Inc.$47K
- Actelion Pharmaceuticals, Ltd$34K
- Bayer$29K
- plus $3K from 1 others
What the payments were for
- Consulting fees$245,68977%
- Speaking & faculty fees$18,2306%
- Travel & lodging$45,27914%
- Food & beverage$10,8943%
- Education$790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 183 | $149,122 |
| Merck | 78 | $62,117 |
| Actelion Pharmaceuticals US, Inc. | 51 | $58,091 |
| Bayer | 33 | $26,110 |
| Actelion Pharmaceuticals, Ltd | 25 | $17,803 |
| Insmed, Inc. | 2 | $4,808 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,500 |
| Liquidia Technologies, Inc. | 1 | $140 |
| Chiesi USA, Inc. | 1 | $110 |
| Janssen Research & Development, LLC | 2 | $109 |
| Boston Scientific | 1 | $89 |
| Sandoz | 3 | $66 |
| GSK | 3 | $54 |
| Amgen | 1 | $35 |
| Pfizer | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$320,171 in reported general payments places this provider in the 95th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 565 | $13,551,207 |
| OpsumitMacitentan | 677 | $8,619,322 |
| Tyvaso DpiTreprostinil | 98 | $2,619,307 |
| AdempasRiociguat | 179 | $2,432,610 |
| WinrevairSotatercept-Csrk | 128 | $2,217,003 |
| OpsynviMacitentan/Tadalafil | 85 | $1,082,747 |
| Ambrisentan | 261 | $841,094 |
| Tadalafil | 466 | $551,811 |
| Orenitram ErTreprostinil Diolamine | 24 | $459,716 |
| LetairisAmbrisentan | 20 | $209,811 |
| RemodulinTreprostinil Sodium | 35 | $167,011 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 157 | $153,851 |
| OfevNintedanib Esylate | 11 | $116,969 |
| Sildenafil Citrate | 323 | $104,219 |
| EliquisApixaban | 50 | $63,242 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit, Opsynvi | $58,091 | $23,253,2771,327 claims |
| BayerAdempas | $26,110 | $2,432,610179 claims |
| MerckWinrevair | $62,117 | $2,217,003128 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $54 | $206,863248 claims |
| United Therapeutics CorporationRemodulin | $149,122 | $167,01135 claims |
| PfizerEliquis | $16 | $63,24250 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 571 pulmonary disease providers in Ohio.
Other pulmonary disease in Cincinnati
- Robert BaughmanCincinnati$640K
- Bruce CorserCincinnati$502K
- Mohammad SheattCincinnati$389K
- Bruce TrapnellCincinnati$92K
- Arun JoseCincinnati$56K
- Francis McCormackCincinnati$19K
- Joseph KhabbazaAkron$655K
- Kristin HighlandCleveland$551K
- Jason StieneckerLima$397K
- Mohammad KhanAkron$388K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.